I would suggest that Treagus is doing the work. Acadia is smashing it because that have a drug in the market already and have just smashed more trial results for the same drug in different disorders. This will allow them to scale manufacturing and distribution channels already in place which is cash in the bank.
Neuren is yet to have a drug enter the market and the MC reflects this. I think Neuren have positioned the business extremely well - just need to land FDA approval and we are away. Some more water to go under the bridge yet, but I think the science is solid and we should expect good things. Just have to have to wait it out.
I would suggest that Treagus is doing the work. Acadia is...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.92 |
Change
0.310(2.28%) |
Mkt cap ! $1.784B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $2.282M | 165.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 143 | $13.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.93 | 678 | 9 |
View Market Depth
| Last trade - 14.13pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |